Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2023 Filed May 19, 2023 20:37 UTC |
Basil Michelle LEVP and General Counsel
|
Tax withholdingCommon Stock | 3,541 | $83.34 | $295,106.94 |
DisclosureSEC source: 0001127602-23-016315 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,469 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:35 UTC |
Llorens JosepEVP, Global Manufacturing
|
Tax withholdingCommon Stock | 1,423 | $83.34 | $118,592.82 |
DisclosureSEC source: 0001127602-23-016313 · form4.xml · nonDerivative · entry 1 Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,463 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:33 UTC |
Miller Laurie A.SVP, Human Resources
|
Tax withholdingCommon Stock | 90 | $83.34 | $7,500.60 |
DisclosureSEC source: 0001127602-23-016311 · form4.xml · nonDerivative · entry 1 Miller Laurie A. · CIK 0001881751 · SVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,766 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:32 UTC |
Simon, ChristopherDirector · President & CEO
|
Tax withholdingCommon Stock | 3,839 | $83.34 | $319,942.26 |
DisclosureSEC source: 0001127602-23-016309 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,367 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:31 UTC |
Strong Stewart WPresident, Global Hospital
|
Tax withholdingCommon Stock | 1,087 | $83.34 | $90,590.58 |
DisclosureSEC source: 0001127602-23-016308 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,147 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2023 Filed May 17, 2023 20:35 UTC |
Strong Stewart WPresident, Global Hospital
|
Tax withholdingCommon Stock | 250 | $89.21 | $22,302.50 |
DisclosureSEC source: 0001127602-23-015947 · form4.xml · nonDerivative · entry 2 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,234 F4 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2023 Filed May 17, 2023 20:34 UTC |
Miller Laurie A.SVP, Human Resources
|
Tax withholdingCommon Stock | 235 | $89.21 | $20,964.35 |
DisclosureSEC source: 0001127602-23-015943 · form4.xml · nonDerivative · entry 2 Miller Laurie A. · CIK 0001881751 · SVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,856 F4 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2023 Filed May 17, 2023 20:31 UTC |
Lingamneni AnilaEVP, Chief Technology Officer
|
Tax withholdingCommon Stock | 318 | $89.21 | $28,368.78 |
DisclosureSEC source: 0001127602-23-015939 · form4.xml · nonDerivative · entry 2 Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,489 F4 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. F3 · balance_after: This number includes unvested RSUs previously reported as well as 297 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 28, 2023. Read SEC document |
| May 16, 2023 Filed May 17, 2023 20:29 UTC |
Llorens JosepEVP, Global Manufacturing
|
Tax withholdingCommon Stock | 319 | $89.21 | $28,457.99 |
DisclosureSEC source: 0001127602-23-015937 · form4.xml · nonDerivative · entry 2 Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,886 F4 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2023 Filed May 17, 2023 20:27 UTC |
Basil Michelle LEVP and General Counsel
|
Tax withholdingCommon Stock | 446 | $89.21 | $39,787.66 |
DisclosureSEC source: 0001127602-23-015931 · form4.xml · nonDerivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,010 F4 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2023 Filed May 17, 2023 20:25 UTC |
Simon, ChristopherDirector · President & CEO
|
Tax withholdingCommon Stock | 1,586 | $89.21 | $141,487.06 |
DisclosureSEC source: 0001127602-23-015925 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,206 F4 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2023 Filed May 17, 2023 20:26 UTC |
DArecca JamesEVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 349 | $89.21 | $31,134.29 |
DisclosureSEC source: 0001127602-23-015929 · form4.xml · nonDerivative · entry 2 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,102 F4 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:36 UTC |
Maunsell Farris MaryanneVP, Chief Accounting Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 1,425 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0001127602-23-015948 · form4.xml · derivative · entry 2 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,425 Underlying: Common Stock · 1,425 shares Expires 2030-05-15 F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:36 UTC |
Maunsell Farris MaryanneVP, Chief Accounting Officer
|
GrantCommon Stock | 630 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015948 · form4.xml · nonDerivative · entry 1 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 630 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:35 UTC |
Strong Stewart WPresident, Global Hospital
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 6,335 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0001127602-23-015947 · form4.xml · derivative · entry 3 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,335 Underlying: Common Stock · 6,335 shares Expires 2030-05-15 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:35 UTC |
Strong Stewart WPresident, Global Hospital
|
GrantCommon Stock | 2,803 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015947 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,484 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:34 UTC |
Miller Laurie A.SVP, Human Resources
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 4,751 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0001127602-23-015943 · form4.xml · derivative · entry 3 Miller Laurie A. · CIK 0001881751 · SVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,751 Underlying: Common Stock · 4,751 shares Expires 2030-05-15 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:34 UTC |
Miller Laurie A.SVP, Human Resources
|
GrantCommon Stock | 2,102 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015943 · form4.xml · nonDerivative · entry 1 Miller Laurie A. · CIK 0001881751 · SVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,091 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:31 UTC |
Lingamneni AnilaEVP, Chief Technology Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,602 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0001127602-23-015939 · form4.xml · derivative · entry 3 Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,602 Underlying: Common Stock · 7,602 shares Expires 2030-05-15 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:31 UTC |
Lingamneni AnilaEVP, Chief Technology Officer
|
GrantCommon Stock | 3,364 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015939 · form4.xml · nonDerivative · entry 1 Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,807 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported as well as 297 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 28, 2023. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:29 UTC |
Llorens JosepEVP, Global Manufacturing
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 6,968 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0001127602-23-015937 · form4.xml · derivative · entry 3 Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,968 Underlying: Common Stock · 6,968 shares Expires 2030-05-15 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:29 UTC |
Llorens JosepEVP, Global Manufacturing
|
GrantCommon Stock | 3,084 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015937 · form4.xml · nonDerivative · entry 1 Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,205 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:28 UTC |
Galvin RoyPresident, Global Plasma & BC
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,068 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0001127602-23-015934 · form4.xml · derivative · entry 2 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,068 Underlying: Common Stock · 5,068 shares Expires 2030-05-15 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:28 UTC |
Galvin RoyPresident, Global Plasma & BC
|
GrantCommon Stock | 2,243 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015934 · form4.xml · nonDerivative · entry 1 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,689 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported as well as 64 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 28, 2023. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:27 UTC |
Basil Michelle LEVP and General Counsel
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,502 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0001127602-23-015931 · form4.xml · derivative · entry 3 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,502 Underlying: Common Stock · 9,502 shares Expires 2030-05-15 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:27 UTC |
Basil Michelle LEVP and General Counsel
|
GrantCommon Stock | 4,205 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015931 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,456 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:25 UTC |
Simon, ChristopherDirector · President & CEO
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 41,177 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0001127602-23-015925 · form4.xml · derivative · entry 3 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,177 Underlying: Common Stock · 41,177 shares Expires 2030-05-15 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:25 UTC |
Simon, ChristopherDirector · President & CEO
|
GrantCommon Stock | 18,225 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015925 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,792 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:26 UTC |
DArecca JamesEVP, Chief Financial Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,502 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0001127602-23-015929 · form4.xml · derivative · entry 3 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,502 Underlying: Common Stock · 9,502 shares Expires 2030-05-15 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:26 UTC |
DArecca JamesEVP, Chief Financial Officer
|
GrantCommon Stock | 4,205 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015929 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,451 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:16 UTC |
Llorens JosepEVP, Global Manufacturing
|
Tax withholdingCommon Stock | 113 | $88.16 | $9,962.08 |
DisclosureSEC source: 0001127602-23-015738 · form4.xml · nonDerivative · entry 1 Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,121 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:17 UTC |
Basil Michelle LEVP and General Counsel
|
Tax withholdingCommon Stock | 204 | $88.16 | $17,984.64 |
DisclosureSEC source: 0001127602-23-015739 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,251 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:15 UTC |
Simon, ChristopherDirector · President & CEO
|
Tax withholdingCommon Stock | 854 | $88.16 | $75,288.64 |
DisclosureSEC source: 0001127602-23-015735 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,567 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported as well as 297 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 28, 2023. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:13 UTC |
Miller Laurie A.SVP, Human Resources
|
Tax withholdingCommon Stock | 32 | $88.16 | $2,821.12 |
DisclosureSEC source: 0001127602-23-015733 · form4.xml · nonDerivative · entry 1 Miller Laurie A. · CIK 0001881751 · SVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,989 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported, 198 shares acquired by the reporting person on October 31, 2022 under the Issuer's 2007 Employee Stock Purchase Plan (as amended, the "ESPP") and 126 shares acquired by the reporting person on April 28, 2023 under the ESPP. Read SEC document |
| May 02, 2023 Filed May 4, 2023 20:27 UTC |
DArecca JamesEVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 430 | $81.66 | $35,113.80 |
DisclosureSEC source: 0001127602-23-014489 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,246 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 22:07 UTC |
Lingamneni AnilaEVP, Chief Technology Officer
|
Tax withholdingCommon Stock | 176 | $84.78 | $14,921.28 |
DisclosureSEC source: 0001127602-23-013161 · form4.xml · nonDerivative · entry 1 Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,146 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:28 UTC |
Llorens JosepEVP, Global Manufacturing
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,391 | $0.00 Strike: $56.57 | $0.00 |
DisclosureSEC source: 0001127602-23-002187 · form4.xml · derivative · entry 3 Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,173 Underlying: Common Stock · 2,391 shares Expires 2028-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:28 UTC |
Llorens JosepEVP, Global Manufacturing
|
SaleCommon Stock | 2,391 | $90.00 | $215,190.00 |
DisclosureSEC source: 0001127602-23-002187 · form4.xml · nonDerivative · entry 2 Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,234 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:28 UTC |
Llorens JosepEVP, Global Manufacturing
|
Exercise / conversionCommon Stock | 2,391 | $56.57 | $135,258.87 |
DisclosureSEC source: 0001127602-23-002187 · form4.xml · nonDerivative · entry 1 Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 21:40 UTC |
Simon, ChristopherDirector · President & CEO
|
GiftCommon Stock | 8,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025631 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,124 F1 · kind: These securities were transferred by the reporting person as a gift without any consideration to the Simon Family 2020 Irrevocable Trust for the benefit of the reporting person's children, which trust has an independent trustee. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:54 UTC |
Galvin RoyPresident, Global Plasma & BC
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,263 | $0.00 Strike: $83.96 | $0.00 |
DisclosureSEC source: 0001127602-22-024920 · form4.xml · derivative · entry 2 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,263 Underlying: Common Stock · 5,263 shares Expires 2029-11-01 F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:54 UTC |
Galvin RoyPresident, Global Plasma & BC
|
GrantCommon Stock | 2,382 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-024920 · form4.xml · nonDerivative · entry 1 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,382 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 20:43 UTC |
Strong Stewart WPresident, Global Hospital
|
SaleCommon Stock | 75 | $80.39 | $6,029.25 |
DisclosureSEC source: 0001127602-22-024416 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,681 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 20:35 UTC |
Basil Michelle LEVP and General Counsel
|
SaleCommon Stock | 180 | $80.39 | $14,470.20 |
DisclosureSEC source: 0001127602-22-024413 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,455 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:50 UTC |
Basil Michelle LEVP and General Counsel
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,011 | $0.00 Strike: $56.57 | $0.00 |
DisclosureSEC source: 0001127602-22-022782 · form4.xml · derivative · entry 7 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,553 Underlying: Common Stock · 1,011 shares Expires 2028-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:50 UTC |
Basil Michelle LEVP and General Counsel
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 4,213 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001127602-22-022782 · form4.xml · derivative · entry 6 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,213 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:50 UTC |
Basil Michelle LEVP and General Counsel
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 3,464 | $0.00 Strike: $38.43 | $0.00 |
DisclosureSEC source: 0001127602-22-022782 · form4.xml · derivative · entry 5 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,464 shares Expires 2024-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:50 UTC |
Basil Michelle LEVP and General Counsel
|
SaleCommon Stock | 11,448 | $78.36 | $897,065.28 |
DisclosureSEC source: 0001127602-22-022782 · form4.xml · nonDerivative · entry 4 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,635 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.75, inclusive. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:50 UTC |
Basil Michelle LEVP and General Counsel
|
Exercise / conversionCommon Stock | 1,011 | $56.57 | $57,192.27 |
DisclosureSEC source: 0001127602-22-022782 · form4.xml · nonDerivative · entry 3 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:50 UTC |
Basil Michelle LEVP and General Counsel
|
Exercise / conversionCommon Stock | 4,213 | $41.64 | $175,429.32 |
DisclosureSEC source: 0001127602-22-022782 · form4.xml · nonDerivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.